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More than 145 mutations have been found in the gene CuZn-Superoxide dismutase (SOD1) in patients with
amyotrophic lateral sclerosis (ALS). The vast majority are easily detected nucleotide mutations in the
coding region. In a patient from a Swiss ALS family with half-normal erythrocyte SOD1 activity, exon flanking
sequence analysis revealed a novel thymine to guanine mutation 7 bp upstream of exon 4 (c.240-7T>G). The
results of splicing algorithm analyses were ambiguous, but five out of seven analysis tools suggested a
potential novel splice site that would add six new base pairs to the mRNA. If translated, this mRNA would
insert Ser and Ile between Glu78 and Arg79 in the SOD1 protein. In fibroblasts from the patient, the predicted
mutant transcript and the mutant protein were both highly expressed, and despite the location of the inser-
tion into the metal ion-binding loop IV, the SOD1 activity appeared high. In erythrocytes, which lack protein
synthesis and are old compared with cultured fibroblasts, both SOD1 protein and enzymic activity was 50% of
controls. Thus, the usage of the novel splice site is near 100%, and the mutant SOD1 shows the reduced stab-
ility typical of ALS-associated mutant SOD1s. The findings suggests that this novel intronic mutation is caus-
ing the disease and highlights the importance of wide exon-flanking sequencing and transcript analysis
combined with erythrocyte SOD1 activity analysis in comprehensive search for SOD1 mutations in ALS.
We find that there are potentially more SOD1 mutations than previously reported.
INTRODUCTION
Five to 10% of patients with amyotrophic lateral sclerosis
(ALS) are diagnosed with a family history of the disease,
familial ALS [FALS (1)]. In these patients, the disease is
genetically heterogeneous, and mutations in nine genes have
been associated with ALS. In most pedigrees, the disease is
inherited as an autosomal dominant trait with complete or
reduced penetrance, but there are also pedigrees with
X-linked and recessive inheritance (2). Mutations in the
gene encoding the antioxidant enzyme CuZn-superoxide dis-
mutase (SOD1) have, in different populations, been identified
in 12–23% of patients with FALS and in 4–7% of all patients
diagnosed with ALS (3). SOD1 is ubiquitously expressed (4)
and composed of two equal subunits each containing a cataly-
tic Cu ion and a stabilizing Zn ion (5).
SOD1, localized at 21q22.1, spans 12 kb, consists of five exons
and encodes a 153-amino acid polypeptide. Since 1993, 145
mutations have been identified in the gene (http://alsod.iop.kcl.
ac.uk/) (6). The majority of these are missense mutations but
13 mutations introduce or delete nucleotides resulting in
C-terminal truncations (7–10). With the exception of D90A
and possibly also of D96N, all other exonic mutations have
been associated with ALS as a dominant trait (11,12). Although
most mutations result in a protein with a reduced SOD1 activity, a
few mutants have been found to possess essentially normal
activity (11,13–15). These findings, combined with the discov-
ery that transgenic mice expressing mutant SOD1s develop
motor neuron disease while homozygous SOD1 knockout mice
do not, have led to the conclusion that mutant SOD1 cause
motor neuron degeneration and ALS because of an acquired
cytotoxic property, the nature of which is poorly understood.
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A few intronic mutations in the SOD1 gene have been
detected in ALS cases (16–18). Such mutations are trouble-
some to detect because a comprehensive search necessitates
complete intron sequencing. Also, when found, their roles
are difficult to interpret. To demonstrate their effect, gene
expression studies have to be performed. Intronic SOD1
mutations can cause splice site aberrations resulting in the del-
etions or insertions of amino acids as well as truncations. Such
perturbations will significantly disrupt the structure and stab-
ility of the SOD1 protein and the result will be a major loss
of erythrocyte SOD1 activity. Therefore, such analysis will
significantly enhance the detection of SOD1 mutations in
ALS. As an example we here report the identification and
characterization of a novel intronic mutation in SOD1 found
in a Swiss patient with FALS.
RESULTS
SOD1 gene and transcript
DNA sequence analyses revealed that the FALS patient was
heterozygous for a sequence variant in intron 3, a T to G
alteration 7 bp upstream of exon 4 (denoted c.240-7T.G)
(Fig. 1A). The significantly lower (50% of controls) SOD1
activity in the erythrocytes of the patient indicated that the
mutation affected the SOD1 translated from the gene. So, to
further investigate the SOD1 gene, we compared the splice
site predictions for the two DNA sequence variants, SOD1
wild-type and SOD1 c.240-7T.G in seven different splice
site prediction analysis tools (Supplementary Material, Table
S1). The results of splicing algorithm analyses were ambigu-
ous, but five of the programs predicted that c.240-7T.G
might introduce a novel acceptor site for exon 4. The
mRNA encoded from the new predicted splice variant would
have six additional base pairs (UAUUAG) inserted between
nucleotides 239 and 240 in the SOD1 mRNA. To verify the
prediction, reverse transcription (RT)–PCR was performed
on RNA from fibroblast lines derived from the ALS patient
and from the control [spinal and bulbar muscular atrophy
(SBMA)]. Agarose gel separation of the amplicons showed
that additional products were amplified in RNA from the
patient fibroblasts compared with RNA from the control fibro-
blasts (Fig. 1B). The two mRNAs seemed to be expressed in
approximately equal amounts. Sequencing of the larger PCR
products (Fig. 1B, lanes 1C and 2C) revealed that the ampli-
con from the SOD1 heterozygous cells is a mix of two frag-
ments that differ in sequence with the bases TATTAG.
Sequence analyses of the subcloned amplicons (Fig. 1B,
lanes 1B and 2B) revealed two different types of fragments.
The wild-type SOD1 sequence and the mutant SOD1 sequence
with the six additional base pairs as expected from the predic-
tion for SOD1 c.240-7T.G (Fig. 1C). Since it was only poss-
ible to clone two of the three bands visible in lane 2B
(Fig. 1B), the third band was concluded to be a heteroduplex
between the wild-type and the mutant amplicons.
The intronic sequence variant was not detected in 245 ana-
lyzed control individuals. The allele frequency of the variant is
thus estimated to be less than 0.002.
SOD1 expression and activity
The mutant mRNA, expressed from the SOD1 c.240-7T.G
allele, is predicted to encode the mutant protein E78_
R79insSI. Western immunoblot analysis of homogenates of
fibroblasts derived from the SOD1 homozygous wild-type
control individual (SBMA) and from the heterozygous FALS
patient showed a slightly broader band in the heterozygote,
suggesting two bands of nearly equal intensities (Fig. 2A).
Estimations by Quantity One suggested that the amount of
SOD1 in the fibroblast extracts from the FALS patient were
85–90% of that in the control. There was no significant
difference between fibroblasts cultured in the presence or
absence of the proteasome inhibitor 4-hydroxy-5-iodo-
3-nitrophenylacetyl-Leu-Leu-Leu-vinylsulfone (NLVS).
Figure 1. (A) Intronic sequence variant found in the FALS patient (heterozygous). The mutation is a single nucleotide exchange, T.G (boxed), in intron 3, 7 bp
upstream of exon 4 (c.240-7T.G ). (B) Additional RT–PCR products (arrows) amplified from fibroblasts heterozygous for the intron sequence variant (lanes 2B
and C) compared with homozygous wild-type fibroblasts (lanes 1B and C). Primer pair A amplifies a 67 bp product from exon 5 in SOD1 (positive control).
Primer pairs B and C amplify a 96 bp product from exons 3 and 4 and a 395 bp product from exons 2–5, respectively. Sizes of the pUC19 DNA/MspI
marker fragments are indicated. (C) Sequence of a TOPO-cloned PCR product from the heterozygous cells (lane 2B) showed that one of the amplicons contains
the additional bases TATTAG as predicted by the splice site analysis tools SplicePort, SpliceView and HSPL.
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Western immunoblot of a hemolysate from the patient and
the two healthy controls showed no indication of two bands
in the heterozyguous patient, and the amount of the SOD1
protein was about half of the controls (Fig. 2B). The SOD1
activity was measured in the fibroblast homogenates and
hemolysate from the ALS patient and controls. In the hemoly-
sate, the activity in the FALS patient was below 50% of the
controls (Table 1).
The SOD1 activity was somewhat lower in the fibroblasts
from the ALS patient than in the control. There were,
however, no obvious differences in SOD1 activity between
the fibroblasts cultured in the presence or absence of the pro-
teasome inhibitor NLVS (Table 2).
DISCUSSION
Genetic screening for SOD1 mutation in FALS has become a
routine in clinical practice and is being performed by several
commercial genetic laboratories. Mutations in the SOD1 gene
is the most frequently identified cause of ALS but in different
populations only 12–23% of patients diagnosed with FALS
and 1–7% of patients with apparently sporadic ALS have
been found to carry mutations in the coding region of the
SOD1 gene (2,3,11,18). In the present study, sequencing of
the coding regions of the five exons revealed no aberrations
but the analysis of the SOD1 activity revealed a 50% reduction.
Further analysis showed that the patient was heterozygous for a
sequence variant in the third intron of SOD1, 7 bp upstream of
exon 4 (c.240-7T.G). The sequence variant and its context
were analyzed for the possibility of additional splice sites in
seven different web-based programs. The outcomes of these
were ambiguous (Supplementary Material, Table S1). Five of
the programs suggested a novel splice site six nucleotides
upstream of exon 4 but only in one of the programs was this
new site predicted to be the strongest. To examine this possi-
bility, we performed RT–PCR on RNA from fibroblasts hetero-
zygous for c.240-7T.G. Indeed, we could confirm that an
additional mRNA with the six predicted extra nucleotides was
transcribed.
Three splice site mutations have been identified in SOD1
previously; all residing in the fourth intron (16–18). One of
these is particularly interesting since it describes a sequence
variant, 304 bp upstream exon 5, that introduces a pseudoexon
into the SOD1 transcript and thus causes a frameshift and a
truncation of the protein (16). Mutations that are positioned
at a significant distance from the exons are easily overlooked
but clearly diseases are sometimes caused by mutations in
splice sites or regulatory elements at significant distances
from the coding regions. Interestingly, there are also human
diseases caused by mutations situated in exons as apparently
missense or non-sense mutations but exerting their disease-
causing effect by changing the splicing of the gene in question
(reviewed in 19–21). These complicated gene expression
regulatory mechanisms emphasize the importance to search
for SOD1 mutations in the non-coding regions and of studying
the expression of the transcript.
Western immunoblot analyses of fibroblast extracts show that
the protein predicted to be encoded by this novel transcript
indeed is expressed (Fig. 2A). The slightly broader band in
the FALS is presumably because E78_R79insSI has a migration
pattern slightly faster than the wild-type SOD1. The insertion
should distort the geometry of loop 4 which contains five of
the ligands to the prosthetic metal ions and C57 which connects
to C146 in a stabilizing intrasubunit disulfide bond. Still the
amount of mutant SOD1 protein in the fibroblast extracts was
close to that seen in the control both in the absence and pres-
ence of NLVS (Fig. 2A), and the mutant protein must possess
Figure 2. (A) Western blot of extracts of fibroblasts, cultured in the presence or absence of NLVS, derived from the control (SBMA) individual and the FALS
patient. A slightly broader band is seen in the FALS patient presumably because of the expression of two SOD1 proteins, E78_R79insSI and wild-type, with
slightly different migration patterns. The samples were loaded undiluted and diluted 1:4. The relative amounts of SOD1 protein in the FALS samples compared
with the corresponding control samples are indicated as percentages. There is no obvious difference between the fibroblasts cultured in the presence or absence of
NLVS. (B) Western blot of a hemolysate from the patient and the two healthy controls. The amount of SOD1 protein in the undiluted FALS sample is approxi-
mately half of that of the undiluted controls (57% estimated by Quantity One) and similar to the amount in the diluted (1:2) controls (88% estimated by
Quantity One).
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some enzymatic activity (Table 2). Severely destabilized SOD1
mutants are only detectable in cells cultured in the presence of a
proteasome inhibitor (22,23). In contrast, in erythrocytes from
the patient, only wild-type SOD1 was found and both SOD1
protein and enzymic activity were half of those in controls
(Fig. 2B and Table 1). In the peripheral blood, erythrocytes
are on average 60 days old and lack protein synthesis but can
eliminate misfolded proteins. A reduction in erythrocyte dismu-
tation activity is therefore a good indicator of the presence of a
destabilizing intronic or exonic SOD1 mutation. The present
results suggest that the mutant SOD1 is destabilized, as has
been found for other ALS-associated mutant SOD1s. Minute
amounts of instable mutant SOD1 protein remaining in erythro-
cytes has previously been shown to correlate with rapid pro-
gression of the disease, which was also seen in our patient
(22,24).
The analyses of mRNA (Fig. 1B), fibroblast extracts
(Fig. 2A) and erythrocytes (Fig. 2B) combine to show that
the usage of the alternative splice site must be close to complete
for the mutant allele, which was only predicted by the program
FSPLICE at www.softberry.com. This splice site analysis tools
also suggested that the normal splice site would be excluded in
the mutant sequence. The high usage is in accordance with a
high disease penetrance suggested by the many ALS patients
in the family. Unfortunately, it was not possible to obtain
samples from relatives of the index patient so it could not be
formally shown that the mutated allele is causative, nor could
the penetrance be evaluated. The mutation was, however, not
found in 245 genotyped Swiss control subjects, nor have our
laboratory found it in more than 5000 ALS patients and
control subjects from Switzerland and other European countries.
We suggest that the here reported mutation is a private mutation
in this isolated Swiss family and that it is most likely the cause
of ALS in the family.
MATERIALS AND METHODS
FALS patient
The proband was a Swiss woman who at the age of 42 years
developed leg-onset muscle wasting with rapid generalization
to all four limbs and later bulbar innervated muscles. The
patient was diagnosed as having ALS according to standard
criteria (25). Despite treatment with non-invasive ventilation,
the patient expired 20 months after symptom onset. The
patient’s mother, an aunt and a second-degree cousin had
earlier died from ALS. The family is described in greater
detail in a separate publication (Weber et al., manuscript in
preparation).
Human tissue
With written informed consent and adhering to the Declaration
of Helsinki (WMA, 1964) venous blood was drawn from the
FALS patient, 245 healthy control subjects (blood donors)
from the same part of Switzerland and, as a control, a
patient with SBMA that had no identified sequence variation
in SOD1. A skin biopsy was obtained from the ALS patient
and the SBMA control patient.
SOD1 genotyping
Genomic DNA was extracted from the buffy coat cells with
DNA extraction kit NUCLEON BACC2 (GE Healthcare, Pis-
cataway, NJ, USA) or FlexiGene DNA Kit (QIAGEN, GmbH,
Germany) according to the manufacturer’s protocol. All five
exons and at least 30 bp of flanking intronic sequences were
amplified with AmpliTaqGould Kit (Applied Biosystems,
Foster City, USA), sequenced using BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems) and read in a
3730 DNA Analyzer (Applied Biosystems). The reactions
were analyzed with SeqScape v2.5 or in Sequence Scanner
v1.0 (Applied Biosystems).
Bioinformatic analysis
The sequence variant found in intron 3 was analyzed for its
possible effect on splicing of the SOD1 transcript in seven
different internet-based analysis tools that make splice site
predictions for submitted sequences (Supplementary Material,
Table S1). The DNA sequence variants c.240-7T.G and its
sequence context (exon 4 and 100 bp upstream and down-
stream) as well as the equivalent wild-type SOD1 sequence
were submitted for analysis.
Human skin fibroblast cell lines
The fibroblast lines were established from skin biopsy speci-
men using standard procedures. The cells were grown to con-
fluence, then passed and kept frozen. For RNA extraction,
fibroblasts were seeded in 8 cm diameter culture discs,
grown to confluence and then scraped off from the disc and
harvested in an isotonic NaCl solution. For SOD1 protein ana-
lyses, the cells were grown in the absence or presence of
10 mM proteasome inhibitor NLVS (Merck, Darmstadt,
Germany), starting 24 h before harvest. The cells were
washed in an isotonic NaCl solution and harvested in APBS
(137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM
KH2PO4) with complete protease inhibitor cocktail with
EDTA (Roche Diagnostics, Indianapolis, IN, USA) and
Table 1. SOD1 activity in erythrocytes from the FALS patient and controls
Erythrocytes from SOD1 (U/mg Hb)
Healthy control 1 54.0
Healthy control 2 56.3
Control (SBMA) 63.4
ALS patient 25.3
Table 2. SOD1 activity in fibroblasts from the FALS patient and a control sub-
ject with SBMA
Fibroblasts from +NLVS treatment SOD1 (U/mg protein)
Control (SBMA) + 126
2 170
ALS patient + 104
2 120
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homogenized by sonication using a Sonifier Cell Disruptor
(Branson, Danbury, CT, USA).
RNA extraction and RT–PCR
Total RNA was extracted from skin fibroblasts using Trizol
reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s description. RT–PCR was performed using
1 mg total RNA and Titan One Tube RT–PCR System
(Roche Diagnostics) according to the manufacturer’s descrip-
tion. Primer pairs used were:
(A) 5′-CAGGTCCATGAAAAAGCAGA-3′ and 5′-CGTTTC
CTGTCTTTGTACTTTC-3′
(B) 5′-AGGCTGTACCAGTGCAGGTC-3′ and 5′-ACATTG
CCCAAGTCTCCAAC-3′
(C) 5′-AGGGCATCATCAATTTCGAG-3′ and 5′-ACAAGC
CAAACGACTTCCAG-3′
Primer pairs A, B and C amplify a 67 bp product from exon
5 in SOD1 (positive control), a 96 bp product from exons 3
and 4 and a 395 bp product from exons 1–5, respectively.
The RT–PCR products were separated on a 4% MetaPhor-
agarose gel (Lonza, Rockland, ME, USA), stained with Ethi-
dium bromide and scanned using a Typhoon 9400 variable
mode imager (GE Healthcare). pUC19 DNA/MspI(HpaII)
marker was used as a length marker to estimate the size of
the amplicons. The larger amplicons (primer pair C) were
sequenced. The smaller amplicons (primer pair B) were cut
from the gel, purified with Freeze ’N Squeeze Spin Columns
(Bio-Rad Laboratories, Hercules, CA, USA) and subcloned
into pCRwII-TOPO-vectors using TOPO TA Cloning-kit
(Invitrogen) and top10 competent cells (Invitrogen). The
cloned fragments were then sequenced.
Sod1 activity and western immunoblot analysis
The SOD1 activity was analyzed as described previously (26).
The amount of protein in the fibroblast homogenates was
determined using the Bio-Rad Protein Assay and the amount
of hemoglobin (Hb) in the hemolysate was determined with
a standard cyanomethemoglobin assay (BR Bioreagens,
Ello¨s, Sweden). The western immunoblots were performed
as described previously (22). The volumes loaded were
adjusted so that the amount of protein or Hb was equal in
all samples. The primary antibody (polyclonal rabbit) used
was raised against a peptide corresponding to the amino
acids 57–72 in the human SOD1 sequence. The chemilumi-
nescence of the blots was recorded in a ChemiDoc apparatus
and the amount of SOD1 protein was analyzed by Quantity
One Software (Bio-Rad Laboratories).
Nomenclature
The novel DNA sequence variant was named according to the
recommendations for nomenclature for the description of
sequence variations proposed by human genome variant
society (HGVS, www.hgvs.org) (27). The NCBI Reference
Sequence NM_000454.4 was used as a reference for the
coding sequence and the A of the first ATG used as residue 1.
Since the first Met is excised in mature SOD1, traditional
SOD1 nomenclature ignores this amino acid. Therefore, the
mutant protein was named E78_R79insSI using the NCBI
Reference Sequence NP_000445.1 as a reference and the
second encoded amino acid (Ala) as residue 1.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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